UA129159C2 - ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1 - Google Patents
ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1 Download PDFInfo
- Publication number
- UA129159C2 UA129159C2 UAA202106566A UAA202106566A UA129159C2 UA 129159 C2 UA129159 C2 UA 129159C2 UA A202106566 A UAA202106566 A UA A202106566A UA A202106566 A UAA202106566 A UA A202106566A UA 129159 C2 UA129159 C2 UA 129159C2
- Authority
- UA
- Ukraine
- Prior art keywords
- compound
- solid
- peaks
- ppm
- magnetic resonance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 | |
| PCT/US2020/030580 WO2020223419A1 (en) | 2019-05-01 | 2020-04-30 | Solid forms of a glyt1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA129159C2 true UA129159C2 (uk) | 2025-01-29 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202106566A UA129159C2 (uk) | 2019-05-01 | 2020-04-30 | ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (https=) |
| EP (1) | EP3962911A1 (https=) |
| JP (2) | JP7513349B2 (https=) |
| KR (1) | KR20220004174A (https=) |
| CN (1) | CN113784966B (https=) |
| AR (1) | AR118839A1 (https=) |
| AU (1) | AU2020266566B2 (https=) |
| BR (1) | BR112021020883A2 (https=) |
| CA (1) | CA3138288A1 (https=) |
| CL (2) | CL2021002837A1 (https=) |
| CO (1) | CO2021014260A2 (https=) |
| CR (1) | CR20210545A (https=) |
| DO (1) | DOP2021000224A (https=) |
| EA (1) | EA202192925A1 (https=) |
| EC (1) | ECSP21082195A (https=) |
| IL (1) | IL287630A (https=) |
| JO (1) | JOP20210295A1 (https=) |
| MA (1) | MA55801A (https=) |
| MX (1) | MX2021013341A (https=) |
| PE (1) | PE20212263A1 (https=) |
| PH (1) | PH12021552741A1 (https=) |
| SG (1) | SG11202111972YA (https=) |
| TW (1) | TW202106680A (https=) |
| UA (1) | UA129159C2 (https=) |
| WO (1) | WO2020223419A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| US11813257B2 (en) | 2020-01-09 | 2023-11-14 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
| WO2025140479A1 (zh) * | 2023-12-29 | 2025-07-03 | 苏州科睿思制药有限公司 | Iclepertin的晶型及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| RS20060190A (sr) * | 2003-10-14 | 2008-08-07 | Pfizer Products Inc., | Biciklični /3.1.0/ derivati kao inhibitori transportera glicina |
| CA2745690A1 (en) * | 2008-12-04 | 2010-06-10 | Evgeny Zlotinikov | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| EP2381941A4 (en) * | 2008-12-29 | 2012-08-01 | Univ Vanderbilt | 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| IL270155B (en) * | 2017-04-27 | 2022-07-01 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| EA202192925A1 (ru) * | 2019-05-01 | 2022-03-23 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердые формы ингибитора glyt1 |
| MX2023001818A (es) * | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| IL301829A (en) * | 2020-10-13 | 2023-06-01 | Boehringer Ingelheim Int | Process of reworking |
-
2020
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en not_active Ceased
- 2020-04-30 AU AU2020266566A patent/AU2020266566B2/en active Active
- 2020-04-30 PH PH1/2021/552741A patent/PH12021552741A1/en unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko not_active Ceased
- 2020-04-30 UA UAA202106566A patent/UA129159C2/uk unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en not_active Abandoned
-
2024
- 2024-03-21 CL CL2024000829A patent/CL2024000829A1/es unknown
- 2024-05-02 JP JP2024074707A patent/JP7714727B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA129159C2 (uk) | ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1 | |
| TWI891687B (zh) | 作為鈉通道調節劑之經取代四氫呋喃 | |
| AU2017254889B2 (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| JP6189299B2 (ja) | プリドピジン塩酸塩の新規な多形形態 | |
| DK3080134T3 (en) | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS | |
| CA2878006C (en) | Carbamate/urea derivatives | |
| JP2017516819A (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体 | |
| WO2016210247A1 (en) | New methods of use for an anti-diarrhea agent | |
| HUE032747T2 (en) | Crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-oxypyridine-4-carbonyl) phenyl] benzenesulfonamide | |
| EA029313B1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| KR20190056398A (ko) | 무스카린 아세틸콜린 수용체 작용제의 결정성 다형체 | |
| JP2019504046A (ja) | チエノピリミジン化合物の結晶形 | |
| UA128408C2 (uk) | Похідні 4-піразин-2-ілметилморфоліну і їх застосування як лікарського засобу | |
| KR20210066848A (ko) | 이속사졸 카르복사미드 화합물 및 이의 용도 | |
| EA045384B1 (ru) | Твердые формы ингибитора glyt1 | |
| CA2876741A1 (en) | Forms of vilazodone and processes for the preparation thereof | |
| SK287355B6 (sk) | Kryštálové formy fenyletanolamínu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú | |
| BG62966B1 (bg) | Нови полиморфни форми на лезопитрон дихидрохлорида и неговите хидратни форми, методи за тяхното получаване и състави, които ги съдържат | |
| AU2108795A (en) | Cyclopropylacetonitrile derivatives, preparation thereof and use thereof as drugs | |
| HK1199027A1 (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 | |
| JPWO2006121104A1 (ja) | ピペリジン環を有するインドール誘導体の結晶およびその製法 |